Ipca Laboratories Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	95,045	89,396	77,050	62,443	58,298	54,200
Other Revenue	153.6	16.3	8.4	37.9	7.1	7.4
Revenue	95,199	89,412	77,059	62,481	58,305	54,207
Revenue Growth (YoY)	9.09%	16.03%	23.33%	7.16%	7.56%	16.58%
Cost of Revenue	31,423	30,815	28,475	25,229	22,080	18,965
Gross Profit	63,776	58,598	48,584	37,252	36,225	35,242
Selling, General & Admin	21,496	20,055	17,314	13,076	11,964	10,309
Other Operating Expenses	23,245	21,618	18,412	14,537	11,374	9,720
Operating Expenses	48,825	45,625	39,268	30,218	25,635	22,097
Operating Income	14,951	12,973	9,316	7,034	10,591	13,146
Interest Expense	-766.4	-843.2	-1,373	-450.9	-72.4	-86.1
Interest & Investment Income	351.2	351.2	629.3	793.5	341.7	369.5
Earnings From Equity Investments	-66.7	-22.9	-62.9	-129.4	-211.6	-77
Currency Exchange Gain (Loss)	330.1	330.1	329.5	-315.1	307.9	413
Other Non Operating Income (Expenses)	60.6	60.6	46.9	110.1	70.4	133.1
EBT Excluding Unusual Items	14,860	12,849	8,886	7,042	11,027	13,898
Merger & Restructuring Charges	-	-	-390.4	-	-	-
Impairment of Goodwill	-	-	-	-	-	-158.4
Gain (Loss) on Sale of Investments	466.2	466.2	547.1	149.7	232.9	101.4
Gain (Loss) on Sale of Assets	27.6	27.6	6.2	160.5	-0.3	-
Asset Writedown	-3.4	-3.4	2.1	-28.4	-113.6	-28.6
Other Unusual Items	-2,457	-2,051	-687.1	-	-	-
Pretax Income	12,894	11,289	8,364	7,324	11,146	13,813
Income Tax Expense	3,483	3,436	3,135	2,534	2,248	2,401
Earnings From Continuing Operations	9,411	7,852	5,229	4,790	8,898	11,411
Minority Interest in Earnings	-312.1	-475.6	244.3	-76.7	-57.1	-11.3
Net Income	9,099	7,377	5,474	4,713	8,841	11,400
Net Income to Common	9,099	7,377	5,474	4,713	8,841	11,400
Net Income Growth	24.73%	34.77%	16.13%	-46.69%	-22.45%	88.02%
Shares Outstanding (Basic)	254	254	254	254	254	253
Shares Outstanding (Diluted)	254	254	254	254	254	253
Shares Change (YoY)	-0.03%	-	-	-	0.17%	0.16%
EPS (Basic)	35.87	29.08	21.57	18.58	34.85	45.01
EPS (Diluted)	35.87	29.08	21.57	18.58	34.85	45.01
EPS Growth	24.78%	34.77%	16.13%	-46.69%	-22.58%	87.73%
Free Cash Flow	-	5,458	5,334	3,113	3,771	7,286
Free Cash Flow Per Share	-	21.51	21.02	12.27	14.87	28.77
Dividend Per Share	2.000	4.000	4.000	4.000	4.000	4.000
Dividend Growth	-50.00%	-	-	-	-	60.00%
Gross Margin	66.99%	65.54%	63.05%	59.62%	62.13%	65.01%
Operating Margin	15.71%	14.51%	12.09%	11.26%	18.16%	24.25%
Profit Margin	9.56%	8.25%	7.10%	7.54%	15.16%	21.03%
Free Cash Flow Margin	-	6.10%	6.92%	4.98%	6.47%	13.44%
EBITDA	18,921	16,668	12,644	9,460	12,749	15,073
EBITDA Margin	19.88%	18.64%	16.41%	15.14%	21.87%	27.81%
D&A For EBITDA	3,970	3,695	3,328	2,427	2,158	1,927
EBIT	14,951	12,973	9,316	7,034	10,591	13,146
EBIT Margin	15.71%	14.51%	12.09%	11.26%	18.16%	24.25%
Effective Tax Rate	27.01%	30.44%	37.48%	34.59%	20.17%	17.39%
Revenue as Reported	96,111	90,324	78,298	63,699	58,964	54,828

Source: S&P Global Market Intelligence. Standard template. Financial Sources.